Biotechnology company Shattuck Labs Inc. (STTK) is advancing innovative therapies for autoimmune and inflammatory diseases, led by SL 325, a potential first-in-class antibody targeting the DR3/TL1A pathway. With a pipeline of bispecific antibodies in development and financing that extends its cash runway into 2029, the company combines scientific progress with long-term stability. These factors, along with recent market momentum, make STTK a name to keep on the radar.
A Signal in the Market
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.